Status:
NOT_YET_RECRUITING
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
Lead Sponsor:
Pfizer
Conditions:
Ulcerative Colitis
Eligibility:
All Genders
18+ years
Brief Summary
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
Detailed Description
Exploring the long-term outcomes of uncontrolled inflammation, and how does early switching to advanced treatments affect disease outcomes and inflammation control in patients with poorly controlled u...
Eligibility Criteria
Inclusion
- Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- Patient enrolled in IBD registry from 2009
- \>18 years at time of diagnosis.
- Diagnosis of Ulcerative Colitis.
- Patient data entered during the study period.
- Minimum duration of data post UC diagnosis (Cohort A: 6 months, Cohort B-D 6 months)
Exclusion
Key Trial Info
Start Date :
December 30 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2026
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT07177209
Start Date
December 30 2025
End Date
March 30 2026
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer
Walton Oaks, United Kingdom, KT20 7NS